Cambridge's TriNetX raises $40M for clinical analytics platform; NovaBay chops its sales force, appoints new chief
→ Merck Global Health Innovation Fund has led a $40 million Series D to support TriNetX in building out and expanding the reach of its clinical analytics platform based on real-world evidence involving 300 million patients. The Cambridge, MA-based company — led by CEO Gadi Lachman — said it will use the funds to accelerate ongoing commercialization in Europe, Asia and South America, adding to its biopharma and CRO customer base as well as healthcare network. New investors Mitsui & Co, ITOCHU Technology Ventures, ITOCHU Corporation, and existing investors MPM Capital, F2 Ventures, and Deerfield Management are also betting on TriNetX’s potential to drive clinical trial design.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.